帕瑞昔布钠与舒芬太尼在肛肠病术后镇痛的应用

Application of Parecoxib Sodium and Sufentanil in Postoperative Analgesia of Anorectal Disease Patients

为比较帕瑞昔布钠和舒芬太尼联合应用与单纯应用舒芬太尼在肛肠病术后的镇痛效果和不良反应，将肛肠病术后病人120例随机分为帕瑞昔布钠组和对照组各60例。手术结束时帕瑞昔布钠组静脉注射帕瑞昔布钠40mg和舒芬太尼1．00pg／ml行静脉自控镇痛（PCIA），12h后帕瑞昔布钠组再静脉注射帕瑞昔布钠40mg；对照组单纯应用舒芬太尼1．50μg／ml行PCIA。观察两组病人术后2，4，6，12h和24h的疼痛强度（VAS评分）、镇痛的补救以及不良反应的发生率。结果显示，与对照组相比，帕瑞昔布钠组术后舒芬太尼用最减少，不良反应发生率降低，术后24h镇痛满意度明显提高（P〈0．05），而两组12h和24h VAS评分无显著性差异（P〉0．05）。结果表明，肛肠病术后静脉注射帕瑞昔布钠可减少术后舒芬太尼的用量，提高病人术后镇痛效果。

The aim of this study was to compare the analgesia efficacy and adverse reaction of parecoxib sodium combined with sufentanil,and alone sufentanil following the operation for anorectal diseases. The 120 patients who had been subjected to operation for their anorectal disease were randomly divided into two groups：parecoxib group and controlled group,60 cases,per group. At the end of operation 40 mg of parecoxib sodium and 1.00μg/ml of sufentanil were intravenously injected with the patients of parecoxib group to performing PCIA, later 12 hr. also injected parecoxib sodium 40 mg; while in controlled group alone 1. 50μg/ml of sufentanil. The pain extent（VAS score） at 2,4,6,12 and 24 hr. after operation,added analgesia,and incidence of adverse reaction were observed and recoreded. As results, the dosage of sufentanil, the incidence of adverse reaction,as well patient＇s satisfactory extent at 24 hr. after operation in parecoxib group was less,decreased and increased,respectively compared with that in controlled group（ P 〈0.05）; but at 12,24 hr. in VAS score there was not significant difference（ P 〉0.05）. Results show that after the operation for anorectal disease intravenously injecting parecoxib sodium can decrease the dosage of sufentanil and enhance the postoperative analgesia efficacy.